Patent Application
20240092916
The present invention relates to a multispecific antibody binding to ActRIIA, ActRIIB, and Fn14.
An activin receptor type 2A (ActRIIA) and an activin receptor type 2B (ActRIIB) are known as receptors for a myostatin and an activin A. Stimulation of ligands to ActRIIA and ActRIIB results in phosphorylation of Smad2 and Smad3. It is known that the phosphorylated Smad2/3 forms a complex with Smad4 and binds to various transcription factors to regulate gene expression (Tsuchida K et al., Endocr J. 2008, Vol. 55, p. 11-21). It is known that in the skeletal muscles, ActRIIA and ActRIIB are involved in proteolysis (Morvan F et al., Proc Natl Acad Sci USA. 2017, vol. 114, p. 12448-12453).
Fibroblast growth factor-inducible 14 (Fn14) (also referred to as TNFRSF12A) is a member of a tumor necrosis factor receptor superfamily. In addition, Fn14 is also known as a TWEAK receptor of a TNF-like weak inducer of apoptosis (TWEAK). Fn14 has TWEAK-dependent activation triggered by the binding of TWEAK and TWEAK-independent activation triggered in the absence of TWEAK. Any of the TWEAK-dependent and TWEAK-independent activations of Fn14 are known to activate an NF-κB signaling pathway and to control cell proliferation, migration, differentiation, and apoptosis, as well as inflammation involved in angiogenesis, tissue damage, and regeneration (Winkles J A, Nat Rev Drug Discov. 2008, Vol. 7, p. 411-425). With regard to the skeletal muscles, it has been reported that the expression of Fn14 increases during pathological conditions and is involved in skeletal muscle atrophy (Non-Patent Document 1). Development of several antibodies binding to Fn14 has hitherto been reported. Many of these antibodies are known to have an antagonistic activity against the activation of Fn14 induced by TWEAK stimulation (hereinafter also simply referred to as an “antagonistic activity”) and an agonistic activity of activating Fn14 in the absence of TWEAK (hereinafter simply an “agonistic activity”) at the same time. A mouse monoclonal antibody, CRCBT-06-002, has been reported to have an antagonistic activity of inhibiting IL-8 production induced by TWEAK stimulation in human malignant melanoma-derived cell line A375 cells. However, it has also been reported to have an agonistic activity of inducing IL-8 production from A375 cells in the absence of TWEAK at the same time (Patent Document 1). In recent years, an antibody binding to Fn14, which has an antagonistic activity but has no agonistic activity, is also known (Patent Document 2).
It has been reported that several factors other than ActRIIA, ActRIIB, and Fn14 are involved in skeletal muscle atrophy (Non-Patent Document 2). A tumor necrosis factor (TNF)α is involved in the degradation of skeletal muscle proteins via a TNF receptor. Glucocorticoids are also involved in the degradation of the skeletal muscle proteins via a glucocorticoid receptor. Skeletal muscle atrophy also occurs due to the suppression of an insulin-like growth factor involved in protein assimilation of skeletal muscles.
Sporadic inclusion body myositis (sIBM) is a chronic progressive muscle disease. Muscle atrophy and muscle weakness are observed mainly in quadriceps femoris muscles or finger or wrist flexors. Characteristic findings of the disease include expression of myofibers accompanied by rimmed vacuoles, and mononuclear cell infiltration or envelopment in non-necrotic myofibers orendomysium. As the disease progresses, decreased walking functions and dysphagia are observed, and the quality of life (QOL) is significantly deteriorated. However, there is currently no established treatment for sIBM (Non-Patent Document 3).
A number of clinical trials on myostatin inhibitors or ActRIIA and ActRIIB inhibitors for muscle diseases have been carried out. Among those, Bimagrumab (Patent Document 3), which is an ActRIIA and ActRIIB inhibitory antibody, is a drug, of which development has been advanced to the highest level, and a Phase II B/Phase III trial has been carried out for sIBM. Although an increase in lean body weight was observed in the Phase II B/Phase III trial of Bimagrumab, an improvement in the primary endpoint of a 6-minute walking distance was not observed (Non-Patent Document 4).
An increase in phosphorylation of Smad2 is observed in the skeletal muscle of an sIBM patient, suggesting the involvement of ActRIIA and ActRIIB stimulation in muscle atrophy (Non-Patent Document 5). In addition, it has been reported that the expression of Fn14 is elevated in the skeletal muscle of an sIBM patient (Non-Patent Document 6). However, no therapeutic agent for sIBM, targeting the inhibition of both pathways of ActRIIA and ActRIIB, and Fn14, has hitherto been reported.
An object of the present invention is to provide a multispecific antibody which is expected to prevent or treat amyotrophic diseases such as inclusion body myositis by binding to ActRIIA, ActRIIB, and Fn14, and inhibiting an amyotrophic action which occurs via ActRIIA, ActRIIB, and Fn14.
The present inventors have conducted repeated studies with considerable ingenuity in the development of a multispecific antibody, and as a result, they have developed a polypeptide binding to ActRIIA and ActRIIB, in which the polypeptide includes a first VHH including CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 65 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 98 to 105 of SEQ ID NO: 2, and a second VHH including CDR1 consisting of the amino acid sequence of amino acid numbers 172 to 176 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 195 to 210 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 243 to 251 of SEQ ID NO: 2 (Example 2). Furthermore, the present inventors have developed a multispecific antibody in which the C terminal of the polypeptide is linked to the N terminal of a heavy chain variable region of an antibody binding to human Fn14 via a peptide linker (Examples 3 and 4). The multispecific antibody binds to ActRIIA, ActRIIB, and Fn14 (Example 5), inhibits phosphorylation of Smad induced by myostatin stimulation (Example 6), inhibits activation of NF-κB induced by TWEAK stimulation (Example 7), and does not induce activation of NF-κB in the absence of TWEAK (Example 7). As a result, the present inventors have provided the multispecific antibody that binds to ActRIIA, ActRIIB, and Fn14, thereby completing the present invention.
According to the present invention, for example, the following inventions are provided.
[1] A multispecific antibody binding to ActRIIA, ActRIIB, and Fn14, the multispecific antibody including:
[2] The multispecific antibody according to [1],
[3] The multispecific antibody according to [1] or [2],
[4] The multispecific antibody according to [1],
[5] The multispecific antibody according to any one of [1] to [4],
[6] The multispecific antibody according to any one of [1] to [4],
[7] The multispecific antibody according to any one of [1] to [6],
[8] The multispecific antibody according to any one of [1] to [4],
[9] The multispecific antibody according to any one of [1] to [4],
[10] The multispecific antibody according to [1],
[11] The multispecific antibody according to any one of [1] to [10],
[12] A polynucleotide including a nucleotide sequence encoding the polypeptide of (a) in the multispecific antibody according to any one of [1] to [4].
[13] A polynucleotide including a nucleotide sequence encoding the heavy chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof in the multispecific antibody according to any one of [5] to [9].
[14] A polynucleotide including a nucleotide sequence encoding the light chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof in the multispecific antibody according to any one of [5] to [9].
[15] A polynucleotide including a nucleotide sequence encoding the polypeptide of (a) and the polypeptide including the heavy chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof in the multispecific antibody according to any one of [1] to [9].
[16] A polynucleotide including a nucleotide sequence encoding the polypeptide in the multispecific antibody according to [10].
[17] A polynucleotide including a nucleotide sequence encoding the light chain of the multispecific antibody according to [10].
[18] An expression vector including the polynucleotide according to any one of [12] to [15].
[19] An expression vector including the polynucleotide according to and/or [15].
[20] An expression vector including the polynucleotide according to and/or [17].
[21] A host cell transfected with the expression vector including the polynucleotide according to any one of [18] to [20].
[22] A host cell transfected with an expression vector including the following polynucleotides of (i) and (ii), or transfected with an expression vector including the following polynucleotide of (i) and/or an expression vector including the following polynucleotide of (ii):
[23] A host cell selected from the group consisting of the following (A) to (D):
[24] A method for producing a multispecific antibody binding to ActRIIA, ActRIIB, and Fn14, the method including a step of culturing a host cell transfected with an expression vector including the following polynucleotides of (i) and (ii), or an expression vector including the following polynucleotide of (i) and an expression vector including the following polynucleotide of (ii) to express the multispecific antibody:
[25] A method for producing a multispecific antibody binding to ActRIIA, ActRIIB, and Fn14, the method including a step of culturing a host cell selected from the group consisting of the following (E) to (G) to express the multispecific antibody:
[26] A multispecific antibody produced by the method according to [24].
[27] A multispecific antibody produced by the method according to [25].
[28] A pharmaceutical composition including:
[29] The pharmaceutical composition according to [28],
[30] A method for preventing or treating inclusion body myositis, the method including administering a therapeutically effective amount of the multispecific antibody according to any one of [1] to [11], [26], and [27].
[31] The multispecific antibody according to any one of [1] to [11], [26], and [27],
[32] A use of the multispecific antibody according to any one of [1] to [11], [26], and [27] in production of a pharmaceutical composition for preventing or treating inclusion body myositis.
The multispecific antibody of the present invention is expected to inhibit phosphorylation of Smad induced by myostatin stimulation and to inhibit activation of Fn14 induced by TWEAK stimulation without exhibiting an agonistic activity, thereby being provided with a muscle atrophy suppressing action. Furthermore, there is a possibility that the multispecific antibody can be used as a prophylactic or therapeutic agent for amyotrophic diseases such as inclusion body myositis.
Hereinafter, the present invention will be described in detail.
There are five classes of IgG, IgM, IgA, IgD, and IgE in an antibody. The basic structure of an antibody molecule is composed of heavy chains having a molecular weight of 50,000 to 70,000 and light chains having a molecular weight of 20,000 to 30,000 in each of the classes in common. The heavy chain usually consists of a polypeptide chain including approximately 440 amino acids, has a distinctive structure for each of the classes, and is referred to as Igγ, Igμ, Igα, Igδ, and Igε corresponding to IgG, IgM, IgA, IgD, and IgE, respectively. Furthermore, four subclasses of IgG1, IgG2, IgG3, and IgG4 are present in IgG, and the heavy chains corresponding thereto are referred to as Igγ1, Igγ2, Igγ3, and Igγ4, respectively. The light chain usually consists of a polypeptide chain including 220 amino acids, two types of which, a type λ and a type κ are known, and are referred to as Igλ, and Igκ. In a peptide configuration of the basic structure of antibody molecules, two homologous heavy chains and two homologous light chains are bound by disulfide bonds (S—S bond) and non-covalent bonds, and the molecular weight thereof is 150,000 to 190,000. Two kinds of light chains can be paired with any heavy chain. Each of the antibody molecules typically consists of two identical light chains and two identical heavy chains.
With regard to intrachain S—S bonds, four S—S bonds are present in the heavy chain (five S—S bonds are present in Igμ and Igε chains), two S—S bonds are present in the light chain, one loop is formed every 100 to 110 amino acid residues, and the steric structures are similar in each loop, which is referred to as a structural unit or a domain. The domain located at the N terminal side in both of the heavy chain and the light chain, whose amino acid sequence is not constant even in a case of a sample from the same class (subclass) of the same kind of animals is referred to as a variable region, and respective domains are referred to as a heavy chain variable region (VH) and a light chain variable region (VL). The amino acid sequence on the C terminal side from the variable region is almost constant for each class or subclass, and is referred to as a constant region (each of the domains of the constant region is represented by CH1, CH2, or CH3 from the N terminal side of the heavy chain constant region, and the light chain constant region is represented by CL).
An antigen-binding site of an antibody is composed of VH and VL, and the binding specificities each depend on the amino acid sequence of this site. On the other hand, biological activities such as binding to complements and various Fc receptor expression cells reflect differences in the constant region structures of each class Ig. It is understood that the variability of the variable regions of the light chains and the heavy chains is almost limited to three small hypervariable regions present in both chains and these regions are referred to as complementarity determining regions (CDR: CDR1, CDR2, and CDR3 from the N terminal side). The remaining portion of the variable region is referred to as a framework region (FR) and is relatively constant.
Various antigen-binding fragments including VH and VL of an antibody also have antigen-binding activities, and representative examples of such antigen-binding fragments include a single chain variable region fragment (scFv), Fab, Fab′, and F(ab′)2. scFv is a monovalent antibody fragment which is composed of VH and VL linked to each other via a linker. Fab is a monovalent antibody fragment which is composed of a light chain and a heavy chain fragment including VH, a CH1 domain, and a portion of a hinge region. Fab′ is a monovalent antibody fragment which is composed of a light chain and a heavy chain fragment including VH, a CH1 domain, and a portion of a hinge region, and the portion of the hinge region includes cysteine residues constituting the S—S bond between heavy chains. The F(ab′)2 fragment is a divalent antibody fragment in which two Fab′ fragments are bound by an S—S bond between heavy chains in the hinge region.
As antibodies derived from camelids (bactrian camels, dromedaries, llamas, and alpacas), antibodies composed only of light chains and CH1 domain-deficient heavy chains (heavy chain antibodies) are known. The variable region of a heavy chain antibody is called a variable domain of a heavy chain of a heavy chain antibody (VHH), and the antigen-binding site of the heavy chain antibody is composed only of VHH. VHH includes three CDRs and the specificity in the binding to an antigen depends on the amino acid sequences of the CDRs.
“VHH” in the present specification also includes humanized forms of VHHs (humanized VHHs), in which a part, the most, or all of the amino acid sequence of FR is substituted with an amino acid sequence derived from a human immunoglobulin molecule. The humanization method is not particularly limited, but for example, a humanized antibody can be produced with reference to International Publication No. 2006/122825, U.S. Pat. Nos. 5,225,539, 6,180,370, and the like.
In the specification, the “multispecific antibody” means an antibody that binds to two or more kinds of different antigens.
In the specification, the “peptide linker” refers to a polypeptide consisting of any one or more amino acid sequences which can be introduced by genetic engineering techniques in order to link variable regions.
<Multispecific Antibody of Present Invention>
The present invention provides the following multispecific antibody (hereinafter also referred to as “the multispecific antibody of the present invention”):
In one embodiment of the multispecific antibody of the present invention, the first VHH and the second VHH are humanized VHHs. In one embodiment of the multispecific antibody of the present invention, the first VHH consists of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and the second VHH consists of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2.
In the polypeptide of (a) in the multispecific antibody of the present invention, the C terminal of the first VHH may be linked to the N terminal of the second VHH, and the C terminal of the second VHH may be linked to the N terminal of the first VHH. In one embodiment of the multispecific antibody of the present invention, the C terminal of the first VHH is linked to the N terminal of the second VHH.
In the polypeptide of (a) in the multispecific antibody of the present invention, the first VHH and the second VHH may be directly linked or linked via a peptide linker. In one embodiment of the multispecific antibody of the present invention, the first VHH and the second VHH are linked via a peptide linker.
In one embodiment of the multispecific antibody of the present invention, the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker. In one embodiment of the multispecific antibody of the present invention, the first VHH and the second VHH are humanized VHHs, and the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker.
In one embodiment of the multispecific antibody of the present invention, the first VHH consists of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2, the second VHH consists of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker.
The length of the peptide linker that links the first VHH and the second VHH is not particularly limited, and can be appropriately selected by those skilled in the art, depending on the purpose. In one embodiment, the first VHH and the second VHH are linked by a peptide linker with 5 amino acids or more, and in one embodiment, the first VHH and the second VHH are linked by a peptide linker with 5 amino acids or more and 35 amino acids or less, 5 amino acids or more and 30 amino acids or less, 5 amino acids or more and 25 amino acids or less, 10 amino acids or more and 25 amino acids or less, or 15 amino acids or more and 25 amino acids or less.
Examples of the peptide linker include the following ones:
[n is an integer of 1 or more]. In one embodiment, the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser (SEQ ID NO: 7)), [n is an integer of 1 to 5], and in one embodiment, the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser)5 (amino acid numbers 117 to 141 of SEQ ID NO: 2).
In one embodiment of the multispecific antibody of the present invention, the first VHH and the second VHH are humanized VHHs, the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser)5 (amino acid numbers 117 to 141 of SEQ ID NO: 2).
In one embodiment of the multispecific antibody of the present invention, the polypeptide of (a) consists of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2.
In one embodiment of the multispecific antibody of the present invention, the antibody binding to Fn14 or an antigen-binding fragment thereof includes a heavy chain variable region including CDR1 consisting of the amino acid sequence of amino acid numbers 303 to 307 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 322 to 338 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 371 to 379 of SEQ ID NO: 2, and a light chain variable region including CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 97 of SEQ ID NO: 4.
In one embodiment of the multispecific antibody of the present invention, the antibody binding to Fn14 or an antigen-binding fragment thereof includes a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4.
In one embodiment of the multispecific antibody of the present invention, the antigen-binding fragment of an antibody binding to Fn14 is an antigen-binding fragment which is scFv, Fab, Fab′, or F(ab′)2.
Any subclass of a constant region (for example, a constant region of Igγ1, Igγ2, Igγ3, or Igγ4 as a heavy chain constant region, and Igλ, or Igκ as a light chain) can be selected as the constant region in the antibody binding to Fn14. In one embodiment, the antibody binding to Fn14 includes a human Igγ1 constant region as the heavy chain constant region and a human Igκ constant region as the light chain constant region.
The residue number related to the introduction of amino acid mutations in the constant region of the antibody used herein can be defined according to the EU index (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institute of Health, Bethesda). L234A is a substitution of leucine at the amino acid 234 position with alanine in the human Igγ1 constant region according to the EU index of Kabat et al. L235A is a substitution of leucine at the amino acid 235 position with alanine in the human Igγ1 constant region according to the EU index of Kabat et al. M252Y is a substitution of methionine at the amino acid 252 position with tyrosine in the human Igγ1 constant region according to the EU index of Kabat et al. S254T is a substitution of serine at the amino acid 254 position with threonine in the human Igγ1 constant region according to the EU index of Kabat et al. T256E is a substitution of threonine at the amino acid 256 position with glutamic acid in the human Igγ1 constant region according to the EU index of Kabat et al.
In one embodiment of the multispecific antibody of the present invention, the multispecific antibody includes an antibody binding to Fn14, and the antibody binding to Fn14 includes a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E. Examples of the constant regions having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E include a human Igγ1 constant region consisting of the amino acid sequence of amino acid numbers 391 to 720 of SEQ ID NO: 2.
In one embodiment of the multispecific antibody of the present invention, the multispecific antibody includes an antibody binding to Fn14, and the antibody binding to Fn14 includes a heavy chain including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E, and a light chain including a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4 and a light chain constant region.
In one embodiment of the multispecific antibody of the present invention, the multispecific antibody includes an antibody binding to Fn14, and the antibody binding to Fn14 includes a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 273 to 720 of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.
In the multispecific antibody of the present invention, the C terminal of the polypeptide of (a) is linked to the N terminal of a heavy chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof via a peptide linker. The length of the peptide linker to be used is not particularly limited, and can be appropriately selected by those skilled in the art, depending on the purpose. In one embodiment, the polypeptide of (a) and the antibody binding to Fn14 or an antigen-binding fragment thereof are linked by a peptide linker with 5 amino acids or more, and in one embodiment, the polypeptide of (a) and the antibody binding to Fn14 or an antigen-binding fragment thereof is linked by a peptide linker with 5 amino acids or more and 35 amino acids or less, 5 amino acids or more and 30 amino acids or less, 5 amino acids or more and 25 amino acids or less, 5 amino acids or more and 20 amino acids or less, or 10 amino acids or more and 20 amino acids or less.
Examples of the peptide linker include the following ones:
[n is an integer of 1 or more]. In one embodiment, the peptide linker that links the polypeptide of (a) and the antibody binding to Fn14 or an antigen-binding fragment thereof is (Gly⋅Gly⋅Gly⋅Gly⋅Ser (SEQ ID NO: 7)), [n is an integer of 1 to 5], and in one embodiment, the peptide linker that links the polypeptide of (a) and the antibody binding to Fn14 or an antigen-binding fragment thereof is (Gly⋅Gly⋅Gly⋅Gly⋅Ser)2 (amino acid numbers 263 to 272 of SEQ ID NO: 2).
In the multispecific antibody of the present invention, the peptide linker that links the first VHH and the second VHH and the peptide linker that links the polypeptide of (a) and the antibody binding to Fn14 or an antigen-binding fragment thereof are the same peptide linker or different peptide linkers.
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention is the following multispecific antibody:
In one embodiment, the multispecific antibody of the present invention includes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence of SEQ ID NO: 4.
It is known that in a case where an antibody is expressed in cells, the antibody is modified after translation. Examples of the post-translational modification include lysine deletion at the C terminal of the heavy chain by a carboxypeptidase, modification of glutamine or glutamic acid at the N terminal of the heavy chain and the light chain to pyroglutamic acid by pyroglutamylation, glycosylation, oxidation, deamidation, and glycation, and it is known that such post-translational modifications occur in various antibodies (Liu H et al., J Pharm Sci. 2008, Vol. 97, p. 2426-2447).
The multispecific antibody of the present invention also includes a post-translationally modified multispecific antibody. In one embodiment, the multispecific antibody of the present invention is a multispecific antibody with pyroglutamylation at the N terminal of the polypeptide of (a) and/or lysine deletion at the heavy chain C terminal of the antibody that binding to Fn14 of the above-described multispecific antibody of the present invention. It is known in the field that such post-translational modification due to pyroglutamylation at the N terminal or lysine deletion at the C terminal does not have any influence on the activity of the antibody (Lyubarskaya Y et al., Anal Biochem. 2006, Vol. 348, p. 24-39).
Any of those skilled in the art can manufacture a fused product from in which the multispecific antibody of the present invention is fused with another peptide or protein, or can also prepare a modified product to which a modifier is bound, based on the present invention, and these forms of multispecific antibodies are also included in the multispecific antibody of the present invention. Other peptides or proteins used for the fusion are not particularly limited as long as the fused product binds to ActRIIA, ActRIIB, and Fn14, and examples thereof include human serum albumin, various tag peptides, artificial helix motif peptides, maltose-binding proteins, glutathione S transferase, various toxins, and other peptides or proteins capable of promoting multimerization. The modifier used for the modification is not particularly limited as long as the modified product binds to ActRIIA, ActRIIB, and Fn14, and examples thereof include polyethylene glycol, sugar chains, phospholipids, liposomes, and low-molecular compounds. In one embodiment, the modifier used to modify the multispecific antibody of the present invention is polyethylene glycol.
The multispecific antibody of the present invention includes a first VHH and a second VHH, binding to ActRIIA and ActRIIB, and an antibody binding to Fn14 or an antigen-binding fragment. The multispecific antibody of the present invention binds to ActRIIA, ActRIIB, and Fn14. Whether or not the multispecific antibody binds to ActRIIA, ActRIIB, or Fn14 can be confirmed using a known binding activity measurement method. Examples of the binding activity measurement method include an Enzyme-Linked immunnoSorbent Assay (ELISA). In a case of using the ELISA, for example, an ActRIIA, ActRIIB, or Fn14 protein is immobilized on an ELISA plate and a test antibody is added thereto to be reacted, and after the reaction, a secondary antibody such as an anti-IgG antibody, labeled with an enzyme such as horseradish peroxidase (HRP), is reacted. After the reaction, washing is performed, and then it is possible to confirm whether the test antibody binds to ActRIIA, ActRIIB, or Fn14 by identifying binding of the secondary antibody through an activity measurement using a reagent detecting the activity (for example, in a case of HRP labeling, TMB Microwell Peroxidase Substrate (Kirkegaard & Perry Laboratories, Inc., 50-76-03)). As a specific measurement method, the method described in Example 5 below can be used.
Examples of the multispecific antibody of the present invention also include multispecific antibodies that bind to not only human ActRIIA, human ActRIIB, and human Fn14, but also ActRIIA, ActRIIB, and Fn14 derived from other animals (mice, monkeys, and the like). In one embodiment, the multispecific antibody of the present invention binds to human ActRIIA, human ActRIIB, and human Fn14.
The multispecific antibody of the present invention can be readily manufactured by those skilled in the art, based on the sequence information of the multispecific antibody of the present invention disclosed in the present specification, using a method known in the art. The multispecific antibody of the present invention is not particularly limited, but can be produced, for example, according to the method described in <Method for Producing Multispecific Antibody of Present Invention> below.
The multispecific antibody of the present invention can be further purified as necessary, formulated according to a standard method, and used for prevention or treatment of amyotrophic diseases such as inclusion body myositis.
<Polynucleotide of Present Invention>
The present invention also provides the following polynucleotides of (1) to (4) (also referred to as “the polynucleotide of the present invention”):
In one embodiment, the polynucleotide of (1) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (1) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, in which the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker. In one embodiment, the polynucleotide of (1) is a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2.
In one embodiment, the polynucleotide of (2) is a polynucleotide including a nucleotide sequence encoding a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (2) is polynucleotide including a nucleotide sequence encoding a heavy chain including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E. In one embodiment, the polynucleotide of (2) is a polynucleotide including a nucleotide sequence encoding a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 273 to 720 of SEQ ID NO: 2.
In one embodiment, the polynucleotide of (3) is a polynucleotide including a nucleotide sequence encoding a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4. In one embodiment, the polynucleotide of (3) is a polynucleotide including a nucleotide sequence encoding a light chain including a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4 and a light chain constant region. In one embodiment, the polynucleotide of (3) is a polynucleotide including a nucleotide sequence encoding a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.
In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and a polypeptide including a heavy chain variable region of an antibody binding to Fn14 or an antigen-binding fragment thereof. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, in which the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and a polypeptide including a heavy chain variable region of an antibody binding to Fn14 or an antigen-binding fragment thereof. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including an amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2 and a polypeptide including a heavy chain variable region of an antibody binding to Fn14 or an antigen-binding fragment thereof.
In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and a polypeptide including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, in which the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and a polypeptide including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2 and a polypeptide including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2.
In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and a polypeptide including a heavy chain including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, in which the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and a polypeptide including a heavy chain including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2, and a polypeptide including a heaving chain including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2 and a heavy chain constant region having amino acid mutations of L234A, L235A, M252Y, S254T, and T256E.
In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and a polypeptide including a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 273 to 720 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide including a first VHH consisting of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and a second VHH consisting of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, in which the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and a polypeptide including a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 273 to 720 of SEQ ID NO: 2. In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2 and a polypeptide including a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 273 to 720 of SEQ ID NO: 2.
In one embodiment, the polynucleotide of (4) is a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2.
Based on the nucleotide sequence, the polynucleotide of the present invention can be readily manufactured by those skilled in the art by using methods known in the art. For example, the polynucleotide of the present invention can be synthesized by using gene synthesis methods known in the art. As such a gene synthesis method, various methods known to those skilled in the art such as a method for synthesizing an antibody gene described in International Publication No. 90/07861 can be used.
<Expression Vector of Present Invention>
The present invention also provides an expression vector including the polynucleotide of the present invention (also referred to as “the expression vector of the present invention”). In one embodiment, the expression vector of the present invention includes any of the polynucleotides of (1) to (4) described in the section of <Polynucleotides of Present Invention>. Specific examples of an embodiment of the polynucleotide included in the expression vector of the present invention include those described for the polynucleotides of (1) to (4) described in the section of <Polynucleotide of Present Invention>.
In one embodiment, the expression vector of the present invention includes (i) a polynucleotide including a nucleotide sequence encoding the light chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof in the multispecific antibody of the present invention and/or (ii) a polynucleotide including a nucleotide sequence encoding the polypeptide including the first VHH and the second VHH (the polypeptide of (a)) and the polypeptide including the heavy chain variable region of the antibody binding to Fn14 or an antigen-binding fragment thereof in the multispecific antibody of the present invention.
Specific examples of an embodiment of the polynucleotides of (i) and (ii) included in the expression vector of the present invention include those described for the polynucleotides of (3) and (4) described in the section of <Polynucleotide of Present Invention>.
In one embodiment, the expression vector of the present invention is an expression vector including a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, an expression vector including a polynucleotide including a nucleotide sequence encoding a light chain consisting of the amino acid sequence of SEQ ID NO: 4, or an expression vector including a polynucleotide including a nucleotide sequence encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a polynucleotide including a nucleotide sequence encoding a light chain consisting of the amino acid sequence of SEQ ID NO: 4.
The expression vector used to express the polynucleotide of the present invention is not particularly limited as long as it can express a polynucleotide including a nucleotide sequence encoding the first VHH of the multispecific antibody of the present invention and a polynucleotide including a nucleotide sequence encoding the second VHH of the multispecific antibody in various host cells of eukaryotic cells (for example, animal cells, insect cells, plant cells, and yeasts) and/or prokaryotic cells (for example, Escherichia coli), and thus, produce a polypeptide encoded therewith. Examples of such an expression vector include plasmid vectors and viral vectors (for example, adenovirus and retrovirus), and for example, plasmid vectors such as pEE6.4 and pEE12.4 can be used. An antibody gene can also be expressed by introducing a variable region gene segment into an expression vector already having a human Ig constant region gene such as AG-γ1 and AG-κ (seem for example, International Publication No. 94/20632).
The expression vector of the present invention may include a promoter operably linked to the polynucleotide of the present invention. Examples of the promoter for expressing the polynucleotide of the present invention in an animal cell include a virus-derived promoter such as CMV, RSV, and SV40, an actin promoter, an elongation factor (EF) 1α promoter, and a heat shock promoter. Examples of the promoter for expressing a polynucleotide by bacteria (for example, Escherichia) include a trp promoter, a lac promoter, a λPL promoter, and a tac promoter. In addition, examples of the promoter for expressing a polynucleotide by a yeast include a GAL1 promoter, a GAL10 promoter, a PHOS promoter, a PGK promoter, a GAP promoter, and an ADH promoter.
In a case where an animal cell, an insect cell, or a yeast is used as a host cell, the expression vector of the present invention can include an initiation codon and a termination codon. In this case, the expression vector of the present invention may include an enhancer sequence, an untranslated region on the 5′ side and the 3′ side of a gene encoding the multispecific antibody of the present invention or the heavy chain variable region or light chain variable region thereof, a secretory signal sequence, a splicing junction, a polyadenylation site, or a replicable unit. In a case where Escherichia coli is used as the host cell, the expression vector of the present invention may include an initiation codon, a termination codon, a terminator region, and a replicable unit. In this case, the expression vector of the present invention may include a selection marker (for example, tetracycline resistant genes, ampicillin resistant genes, kanamycin resistant genes, neomycin resistant genes, or dihydrofolate reductase genes) which is generally used according to the purpose.
<Transfected Host Cell of Present Invention>
The present invention also provides a host cell transfected with the expression vector of the present invention (also referred to as “the transfected host cell of the present invention”). In one embodiment, the host cell of the present invention is a host cell transfected with an expression vector including any of the polynucleotides of (1) to (4) described in the section of <Polynucleotide of Present Invention>. Specific examples of an embodiment of the polynucleotide included in the expression vector include those described for the polynucleotides of (1) to (4) described in the section of <Polynucleotide of Present Invention>.
In one embodiment, the host cell of the present invention is a host cell transfected with an expression vector including the following polynucleotide of (i) and/or (ii), or an expression vector including the following polynucleotide of (i) and/or an expression vector including the following polynucleotide of (ii):
Specific examples of the embodiment of the polynucleotides of (i) and (ii) in the host cell of the present invention include those described for the polynucleotides of (3) and (4) described in the section of <Polynucleotide of Present Invention>.
In one embodiment, the transfected host cell of the present invention includes a host cell transfected with an expression vector of the present invention, selected from the group consisting of the following (A) to (D):
The transfected host cell is not particularly limited as long as the host cell is appropriate for an expression vector to be used, transfected with the expression vector, and can express the multispecific antibody. Examples of the transfected host cell include various cells such as natural cells or artificially established cells which are generally used in the field of the present invention (for example, animal cells (for example, CHO-K1SV cells), insect cells (for example, Sf9), bacteria (for example, Escherichia), yeast (for example, Saccharomyces or Pichia) and the like). For example, cultured cells such as CHO cells (CHO-K1SV cells and CHO-DG44 cells), 293 cells, and NS0 cells can be used.
A method for transfecting the host cell is not particularly limited, and for example, a calcium phosphate method or an electroporation method can be used.
<Method for Producing Multispecific Antibody of Present Invention>
The present invention also provides a method for producing a multispecific antibody binding to ActRIIA, ActRIIB, and Fn14, the method including a step of culturing the transfected host cell of the present invention to express the multispecific antibody (also referred to as “the production method of the present invention”).
In one embodiment, the production method of the present invention includes a step of culturing a host cell transfected with an expression vector including the following polynucleotides of (i) and (ii), or an expression vector including the following polynucleotide of (i) and an expression vector including the following polynucleotide of (ii) to express the multispecific antibody:
Specific examples of the embodiment of the polynucleotides of (i) and (ii) in the production method of the present invention include those described for the polynucleotides of (3) and (4) described in the section of <Polynucleotide of Present Invention>.
In one embodiment, the production method of the present invention is a method for producing a multispecific antibody binding to ActRIIA, ActRIIB, and Fn14, the method including a step of culturing a host cell selected from the group consisting of the following (A) to (C) to express the multispecific antibody:
The transfected host cell can be cultured by a known method. The culture conditions, for example, the temperature, the pH of culture medium, and the culture time are appropriately selected. In a case where the host cell is an animal cell, examples of the culture medium include MEM culture medium supplemented with approximately 5% to 20% of fetal bovine serum (Eagle H, Science. 1959, Vol. 130, p. 432-437), DMEM culture medium (Dulbecco R and Freeman G, Virology. 1959, Vol. 8, p. 396-397), RPMI1640 culture medium (Moore G E et al., JAMA. 1967, Vol. 199, p. 519-524), and 199 culture medium (Morgan J F et al., Proc Soc Exp Biol Med. 1950, Vol. 73, p. 1-8). The pH of the culture medium is preferably approximately 6 to 8, and the culturing is generally performed at approximately 30° C. to 40° C. for approximately 15 to 336 hours under optional ventilation or stirring. In a case where the host cell is an insect cell, as the culture medium, for example, Grace's culture medium (Smith G E et al., Proc Natl Acad Sci USA, 1985, Vol. 82, p. 8404-8408) supplemented with fetal bovine serum can be used. The pH of the culture medium is preferably approximately 5 to 8, and the culturing is generally performed at approximately 20° C. to 40° C. for approximately 15 hours to 100 hours under optional ventilation or stirring. In a case where the host cell is Escherichia coli or yeast, as the culture medium, for example, liquid culture medium supplemented with a source of nutrients is appropriate. The nutrient culture medium preferably includes a carbon source, an inorganic nitrogen source, or an organic nitrogen source necessary for the growth of the transfected host cell. Examples of the carbon source include glucose, dextran, soluble starch, and sucrose and examples of the inorganic nitrogen source or the organic nitrogen source include ammonium salts, nitrate salts, amino acids, corn steep liquor, peptone, casein, meat extract, soybean meal, and potato extract. Other nutrients (for example, inorganic salts (for example, calcium chloride, sodium dihydrogen phosphate, and magnesium chloride), vitamins), and antibiotics (for example, tetracycline, neomycin, ampicillin, and kanamycin) may be included as desired. The pH of the culture medium is preferably approximately 5 to 8. In a case where the host cell is Escherichia coli, for example, LB culture medium or M9 culture medium (Mol. Clo., Cold Spring Harbor Laboratory, 2001, Vol. 3, A2.2) can be preferably used as the culture medium. The culturing is generally performed at approximately 14° C. to 39° C. for approximately 3 to 24 hours under optional ventilation or stirring. In a case where the host cell is yeast, for example, Burkholder minimal medium (Bostian K A et al., Proc Natl Acad Sci USA. 1980, Vol. 77, p. 4504-4508) can be used as the culture medium. The culturing is generally performed at approximately 20° C. to 35° C. for approximately 14 to 144 hours under optional ventilation or stirring. The multispecific antibody of the present invention can be expressed by the culturing as described above.
The method for producing the multispecific antibody of the present invention can further include, in addition to the steps of culturing the transfected host cell of the present invention to express the multispecific antibody, a step of recovering, for example, isolating or purifying a multispecific antibody from the transfected host cell and/or the culture supernatant. Examples of the isolation or purification method include methods using solubility such as salting-out and a solvent precipitation method, methods using the difference in molecular weight such as dialysis, ultrafiltration, and gel filtration, methods using an electric charge such as ion exchange chromatography and hydroxylapatite chromatography, methods using specific affinity such as affinity chromatography, methods using the difference in hydrophobicity such as reverse phase high performance liquid chromatography, and methods using the difference in the isoelectric point such as isoelectric focusing electrophoresis. For example, the antibody accumulated in the culture supernatant can be purified by various types of chromatography, for example, column chromatography using a Protein A column or a Protein G column.
The multispecific antibody of the present invention also include a multispecific antibody produced by the method of producing a multispecific antibody of the present invention.
<Pharmaceutical Composition of Present Invention>
The present invention also provides a pharmaceutical composition (also referred to as “the pharmaceutical composition of the present invention”) including the multispecific antibody of the present invention and a pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be prepared by a generally used method with an excipient generally used in the field, that is, a pharmaceutical excipient, a pharmaceutical carrier, or the like. Examples of a dosage form of the pharmaceutical composition include parenteral drug such as an injection drug and a drip infusion drug, and these can be administered by intravenous administration, subcutaneous administration, intramuscular administration, or the like. In the drug formulation, an excipient, a carrier, an additive, and the like can be used according to the dosage form within a pharmaceutically acceptable range.
The pharmaceutical composition of the present invention may include a multispecific antibody generated by a post-translational modification of the multispecific antibody of the present invention. The pharmaceutical composition of the present invention may include a plurality of kinds of multispecific antibodies of the present invention. In one embodiment, the pharmaceutical composition of the present invention contain the multispecific antibody of the present invention and a multispecific antibody generated by a post-translational modification of the multispecific antibody. In one embodiment, the multispecific antibody generated by the post-translational modification includes N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of the heavy chain of an antibody binding to Fn14 (also simply referred to as an “Fn14 antibody”).
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, and the multispecific antibody of the present invention includes:
In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition containing the multispecific antibody of the present invention and/or a multispecific antibody generated by a post-translational modification of the multispecific antibody, in which the multispecific antibody of the present invention includes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence of SEQ ID NO: 4. In one embodiment, the post-translational modification is N-terminal pyroglutamylation of the polypeptide of (a) and/or deletion of C-terminal lysine of a heavy chain of the Fn14 antibody.
In one embodiment, the pharmaceutical composition of the present invention contains one kind or two or more kinds of multispecific antibodies selected from the following (c) to (f).
The amount of the multispecific antibody of the present invention added in the formulation varies depending on the degree of a patient's symptom, the age of a patient, a dosage form of a drug to be used, a binding titer of the antibody, or the like, and for example, the antibody or antigen-binding fragment thereof can be used such that the amount of the antibody or antigen-binding fragment thereof is approximately 0.001 mg/kg to 100 mg/kg during the administration.
The pharmaceutical composition of the present invention can be used as a prophylactic or therapeutic agent for diseases in which ActRIIA, ActRIIB, and Fn14 are involved in pathogenesis, such as inclusion body myositis.
The present invention includes a pharmaceutical composition for preventing or treating inclusion body myositis, the pharmaceutical composition including the multispecific antibody of the present invention. In addition, the present invention includes a method for preventing or treating inclusion body myositis, the method including administering a therapeutically effective amount of the multispecific antibody of the present invention. Moreover, the present invention also includes the multispecific antibody of the present invention for use in prevention or treatment of inclusion body myositis. Furthermore, the present invention includes a use of the multispecific antibody of the present invention in the production of a pharmaceutical composition for preventing or treating inclusion body myositis.
<Polypeptide Binding to ActRIIA and ActRIIB>
The present invention also provides the following polypeptide binding to ActRIIA and ActRIIB (hereinafter also referred to as “the ActRIIA/B-binding peptide of the present invention”):
In one embodiment, the first VHH and the second VHH are humanized VHHs. In one embodiment, the first VHH consists of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and the second VHH consists of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2.
In the ActRIIA/B-binding peptide of the present invention, the C terminal of the first VHH may be linked to the N terminal of the second VHH, and the C terminal of the second VHH may be linked to the N terminal of the first VHH. In one embodiment, the C terminal of the first VHH is linked to the N terminal of the second VHH.
In the ActRIIA/B-binding peptide of the present invention, the first VHH and the second VHH may be directly linked or linked via a peptide linker. In one embodiment, the first VHH and the second VHH are linked via a peptide linker.
In one embodiment, the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker. In one embodiment, the first VHH and the second VHH are humanized VHHs, and the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker.
In one embodiment, the first VHH consists of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2, the second VHH consists of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2, and the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker.
The peptide linker that links the first VHH and the second VHH is not particularly limited, and for example, the peptide linker exemplified as the peptide linker that links the first VHH and the second VHH in the section <Multispecific Antibody of Present Invention> can be used. In one embodiment, the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser (SEQ ID NO: 7)), [n is an integer of 1 to 5], and in one embodiment, the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser)5 (amino acid numbers 117 to 141 of SEQ ID NO: 2).
In one embodiment, the first VHH and the second VHH are humanized VHHs, the C terminal of the first VHH is linked to the N terminal of the second VHH via a peptide linker, and the peptide linker that links the first VHH and the second VHH is (Gly⋅Gly⋅Gly⋅Gly⋅Ser)5 (amino acid numbers 117 to 141 of SEQ ID NO: 2). In one embodiment, the ActRIIA/B-binding peptide of the present invention consists of the amino acid sequence of amino acid numbers 1 to 262 of SEQ ID NO: 2 Any of those skilled in the art can manufacture a fused product from in which the ActRIIA/B-binding peptide of the present invention is fused with another peptide or protein, or can also prepare a modified product to which a modifier is bound, based on the present invention, and these fused products and modified products thereof are also included in the ActRIIA/B-binding peptide of the present invention. Other peptides or proteins used for the fusion are not particularly limited as long as the fused product binds to ActRIIA and ActRIIB, and examples thereof include an antibody or antigen-binding fragment thereof, human serum albumin, various tag peptides, artificial helix motif peptide, maltose-binding proteins, glutathione S transferase, various toxins, and other peptides or proteins capable of promoting multimerization. The modifier used for the modification is not particularly limited as long as the modified product binds to ActRIIA and ActRIIB and examples thereof include polyethylene glycol, sugar chains, phospholipids, liposomes, and low-molecular compounds. In one embodiment, the modifier used to modify the ActRIIA/B-binding peptide of the present invention is polyethylene glycol.
The ActRIIA/B-binding peptide of the present invention, and a fused product and a modified product thereof can be readily manufactured by those skilled in the art, using a method known in the art, based on sequence information of VHHs, other peptides or proteins (for example, an antibody) used in the fused product, and information on a modifier used in the modified product. The ActRIIA/B-binding peptide of the present invention is not particularly limited, but can be produced, for example, according to the method described in the section of <Method for Producing Multispecific Antibody of Present Invention>.
Specific examples are provided herein for reference in order to obtain further understanding of the present invention; however, these examples are for the purpose of illustration and the present invention is not limited thereto.
With regard to parts using commercially available kits, reagents, or the like, experiments were conducted according to an attached protocol unless otherwise specified.
The present inventors immunized an alpaca multiple times with proteins including the extracellular domain of ActRIIB in order to acquire a VHH targeting the extracellular domain of ActRIIB. After completion of the immunization, blood was collected from the alpaca, alpaca peripheral blood lymphocytes were separated from the collected blood sample, and an immune library for a phage display was constructed according to a known method (Miyazaki N et al., J Biochem. 2015, Vol. 158, p. 205-215). Biopanning for the extracellular domain of ActRIIB using the phage display was performed on a protein including the extracellular domain of ActRIIB, a stably expressing cell line in which a human ActRIIB gene (NCBI accession number: NM_001106.4) was introduced into CHO cells (hereinafter referred to as ActRIIB/CHO cells), and a stably expressing cell line in which a human ActRIIB gene (NCBI accession number: NM_001106.4) was introduced into HEK293 cells (hereinafter referred to as ActRIIB/HEK293 cells). Biopanning targeting a protein including the extracellular domain of ActRIIB was performed according to a known method (Miyazaki N et al., J Biochem. 2015, Vol. 158, p. 205-215). In the biopanning targeting the ActRIIB/CHO cells or the ActRIIB/HEK293 cells, a phage bound to each cell was acquired by a method in which the phage library and each cell were mixed and repeatedly subjected to a washing operation several times, and then the phage bound to the cell was eluted from the phage/cell complex with an acid. A plurality of phages binding to the extracellular domain of ActRIIB were acquired by the biopanning. The VHH-encoding genes were cloned from the acquired phage and sequenced.
Among the VHHs obtained in Example 1, a plurality of libraries in which genes encoding any two VHHs were linked to genes encoding peptide linkers with various lengths (also referred to as GS linkers) composed of Gly and Ser for the phage display were constructed and subjected to biopanning in the same manner as in Example 1. Biopanning for the extracellular domain of ActRIIA and the extracellular domain of ActRIIB using the phage display was performed on a protein including the extracellular domain of ActRIIA, a protein including the extracellular domain of ActRIIB, a stably expressing cell line in which a human ActRIIA gene (NCBI accession number: AB529011.1) was introduced into CHO cells (hereinafter referred to as ActRIIA/CHO cells), and ActRIIB/CHO cells. As a result of evaluating a plurality of tandem VHHs, a tandem VHH binding to the extracellular domains of ActRIIA and ActRIIB was acquired. The tandem VHH is referred to as 75E9. Then, the tandem VHH 75E9 was humanized according to examples of International Publication No. 2006/122825 and the like. This is referred to as a humanized tandem VHH 75E9.
The amino acid sequence of the humanized tandem VHH 75E9 is set forth in amino acid numbers 1 to 262 of SEQ ID NO: 2. The first VHH in the humanized tandem VHH 75E9 set forth in amino acid numbers 1 to 262 of SEQ ID NO: 2 consists of the amino acid sequence of amino acid numbers 1 to 116 of SEQ ID NO: 2 and the second VHH consists of the amino acid sequence of amino acid numbers 142 to 262 of SEQ ID NO: 2.
CDR1, CDR2, and CDR3 of the first VHH of the humanized tandem VHH 75E9 consist of amino acid sequences from amino acid numbers 31 to 35, 50 to 65, and 98 to 105 of SEQ ID NO: 2, respectively. CDR1, CDR2, and CDR3 of the second VHH of the humanized tandem VHH 75E9 consist of amino acid sequences from amino acid numbers 172 to 176, 195 to 210, and 243 to 251 of SEQ ID NO: 2, respectively.
In order to acquire an antibody binding to human Fn14 expressed on a cell surface, the present inventors prepared a human Fc fusion protein including the extracellular domain of human Fn14 according to Example 1 of International Publication No. 2020/090892, constructed a stably expressing cell line in which a human Fn14 gene (NCBI accession number: NM_016639) was introduced into Jurkat cells (hereinafter referred to as Fn14/Jurkat cells), and used for immunization and screening. Furthermore, an antibody was developed using a human monoclonal antibody developing technology “VelocImmune” (VelocImmune antibody technology: Regeneron Pharmaceuticals, Inc. (U.S. Pat. No. 6,596,541)) mouse. The antibody obtained by the VelocImmune technology is an antibody having a variable region of a human antibody and a constant region of a mouse antibody. VelocImmune mice were immunized with an adjuvant for causing an immune reaction together with a human Fn14 protein in which a human Fc region was cut and removed from the human Fc fusion protein including the extracellular domain of a human Fn14 prepared above by using FabRICATOR (Sigma, 77661), and the Fn14/Jurkat cells, alternately. Lymphocytes collected from the lymph node of the immunized mouse were fused with mouse-derived myeloma cells SP2/0-Ag14 (ATCC: CRL-1581) according to a standard method to generate hybridomas, and the hybridomas were monocloned. Hybridomas producing an antibody, which binds to human Fn14 and Fn14/Jurkat cells and suppresses the NF-κB activation induced by TWEAK stimulation (hereinafter referred to as TWEAK-induced NF-κB activation in Examples below), were selected. Further, the genes encoding the heavy chain and the light chain of the antibody were cloned from the hybridomas, and the sequence was determined. A gene encoding a human Igγ1 constant region having amino acid mutations of L234A and L235A, and a gene encoding a signal sequence (Whittle N et al., Protein Eng. 1987, Vol. 1, p. 499-505) were linked to the 3′ side and the 5′ side of the gene encoding the heavy chain variable region of this antibody (corresponding to a nucleotide sequence encoding amino acid numbers 273 to 390 of SEQ ID NO: 2) (SEQ ID NO: 13), respectively, and inserted into a GS vector pEE6.4 (Lonza). SEQ ID NO: 14 is a sequence obtained by translating SEQ ID NO: 13 into amino acids. In addition, a gene encoding the signal sequence and a gene encoding the constant region of a human κ chain (corresponding to a nucleotide sequence encoding amino acid numbers 109 to 214 of SEQ ID NO: 4) were linked to the 5′ side and the 3′ side of the gene encoding the light chain variable region of this antibody (corresponding to a nucleotide sequence encoding amino acid numbers 1 to 108 of SEQ ID NO: 4), respectively, and inserted into GS vector pEE12.4 (Lonza). A double-gene vector (hereinafter referred to as DGV) into which both the heavy chain and light chain genes were inserted was constructed from these GS vectors. The antibody was purified from the culture supernatant of CHO-K1SV cells transfected with this vector according to a standard method. This antibody is referred to as STF8-1.
The heavy chain variable region of STF8-1 consists of the amino acid sequence of amino acid numbers 273 to 390 of SEQ ID NO: 2. The light chain variable region of STF8-1 consists of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4.
CDR1, CDR2, and CDR3 of the heavy chain variable region of STF8-1 consist of amino acid sequences from amino acid numbers 303 to 307, 322 to 338, and 371 to 379 of SEQ ID NO: 2, respectively. CDR1, CDR2, and CDR3 of the light chain variable region of STF8-1 consist of amino acid sequences from amino acid numbers 24 to 34, 50 to 56, and 89 to 97 of SEQ ID NO: 4, respectively.
A polynucleotide in which a gene encoding the signal sequence, a gene encoding humanized tandem VHH 75E9 (corresponding to nucleotide numbers 1 to 786 of SEQ ID NO: 1), a gene encoding a GS linker (corresponding to nucleotide numbers 787 to 816 of SEQ ID NO: 1), a gene encoding the heavy chain variable region of STF8-1 (corresponding to nucleotide numbers 817 to 1170 of SEQ ID NO: 1), and a gene (corresponding to nucleotide numbers 1171 to 2160 in SEQ ID NO: 1) encoding a human Igγ1 constant region having amino acid mutations of L234A and L235A and amino acid mutations of M252Y, S254T, and T256E (International Publication No. 2002/060919) were linked in this order was inserted into a GS vector pEE6.4 (Lonza). In addition, a gene encoding the signal sequence and a gene (corresponding to nucleotide numbers 325 to 642 of SEQ ID NO: 3) encoding a constant region of a human κ chain were each linked to the 5′ side and the 3′ side of a gene (corresponding to nucleotide numbers 1 to 324 of SEQ ID NO: 3) of a light chain variable region of STF8-1, and inserted into a GS vector pEE12.4 (Lonza). DGVs into which both the heavy and light chain genes were inserted were constructed from these GS vectors. The antibody was purified from the culture supernatant of CHO-K1SV cells transfected with this vector according to a standard method. This antibody is referred to as humanized 75E9STF8-1.
The binding activities of the humanized 75E9STF8-1 obtained in Example 4 to ActRIIA, ActRIIB, and Fn14 were evaluated. ActRIIA-His (LifeSpan Biosciences, LS-G39063), ActRIIB-His (LifeSpan Biosciences, LS-G38834), and the human Fc fusion proteins including the extracellular domain of human Fn14 prepared in Example 3 were each diluted to 1 μg/mL with phosphate-buffered physiological saline (PBS), each added to a Maxisorp 384-well transparent plate (Nunc, 464718) at 15 μL/well, and incubated at 4° C. overnight for immobilization. On the next day, the solid phase liquid was removed and washing was performed with a 0.05% Tween-20-containing Tris-buffered physiological saline (TBS-T). Thereafter, PBS including 20% Blocking One (Nacalai tesque, Inc., 03953-95) was added thereto at 50 μL/well, and the mixture was left to stand at room temperature for 1 hour and then washed with TBS-T. Dilution series of humanized 75E9STF8-1 were prepared by dilution in 12 steps at a 4-fold common ratio from the maximum concentration of 30 μg/mL, and added at 20 μL/well. TBS-T including 5% Blocking One was used as a diluent. After incubation for 1 hour at room temperature, washing was performed with TBS-T. As a detection antibody, Goat Anti-Human Kappa, Mouse ads-HRP (SouthernBiotech, 2061-05) which had been 4,000-fold diluted with a diluent (TBS-T including 5% Blocking One) was added at 20 μL/well. After incubating at room temperature for 1.5 hours, the cells were washed with TBS-T, TMB+Substrate-Chromogen (DAKO, S159985) was added thereto, the mixture was left to stand, 1 M sulfuric acid was added thereto to stop the reaction, and the absorbance at 450 nm was measured with Infinite (registered trademark) 200 Pro (TECAN).
As a result, humanized 75E9STF8-1 bound to ActRIIA-His (EC50=5.03 ng/mL), ActRIIB-His (EC50=9.24 ng/mL), and a human Fc fusion protein including the extracellular domain of human Fn14 (EC50=23.3 ng/mL).
The inhibitory action of humanized 75E9STF8-1 on myostatin-induced Smad3 phosphorylation in ActRIIA and ActRIIB was evaluated. A stably expressing cell line in which a human ActRIIA gene (NCBI accession number: AB529011.1) was introduced into HEK293 cells (hereinafter referred to as ActRIIA/HEK293 cells), and ActRIIB/HEK293 cells were used for evaluation.
ActRIIA/HEK293 cells or ActRIIB/HEK293 cells were suspended in a 10% fetal bovine serum-containing DMEM (Sigma, D6429) at 2×10 5 cells/mL, and seeded on a collagen I-coated 96-well plate (IWAKI, 4860-010) at 100 μL/well. The resultant was cultured overnight in a CO2 incubator set at 37° C. and 5% CO2. After the culturing, the medium was removed by centrifugation, and 80 μL of a 2% fetal bovine serum-containing DMEM was added to each well. The resultant was cultured overnight in a CO2 incubator under the same conditions as above. Dilution series of the humanized 75E9STF8-1 were prepared by dilution in 8 steps at an about 3-fold common ratio from the maximum concentration of 300 nmol/L for the ActRIIA/HEK293 cells and from the maximum concentration of 1,000 nmol/L for the ActRIIB/HEK293 cells, and added at 10 μL/well. In addition, the same dilution series of Bimagrumab were added as a control. A 2% fetal bovine serum-containing DMEM was used as a dilution solvent. The resultant was cultured for 15 minutes in a CO2 incubator under the same conditions as above. Thereafter, 10 μL/well of myostatin (PEPROTECH, 120-00) prepared in a 2% fetal bovine serum-containing DMEM was added to a final concentration of 100 ng/mL. After culturing for 1 hour in a CO2 incubator under the same conditions as above, the medium was removed by centrifugation, a lysis buffer in an AlphaLISA (registered trademark) SureFire (registered trademark) Ultra™ SMAD3 (p-Ser423/425) assay kit (PerkinElmer, ALSU-PSM3) was added to the resultant at 50 μL/well and dissolved by stirring at room temperature for 10 minutes to lyse the cells. Phosphorylated Smad3 in the cell lysate was detected using the kit. The results are expressed in terms of an inhibition rate in a case where a value measured under the condition of 100 ng/mL myostatin stimulation and a value measured in the absence of myostatin are set to 0% inhibition and 100% inhibition, respectively. Measurements in the absence of myostatin were carried out by adding a medium instead of myostatin. Furthermore, the data represent an average value of 2 trials (each trial was carried out in duplicate).
As a result, the humanized 75E9STF8-1 inhibited myostatin-induced Smad3 phosphorylation in the ActRIIA/HEK293 cells and ActRIIB/HEK293 cells (
Activation of Fn14 in the presence or absence of TWEAK activates NF-κB as a downstream signal. In order to evaluate the antagonistic activity of humanized 75E9STF8-1, this signal was used as an index to evaluate the inhibitory action of TWEAK-induced NF-κB activation in human Fn14. In addition, as an evaluation of the agonistic activity of humanized 75E9STF8-1, the NF-κB activation action was evaluated in the absence of TWEAK. Specifically, the action of humanized 75E9STF8-1 on NF-κB activation in the presence or absence of TWEAK was evaluated in a reporter assay. HEK293 cells into which a luciferase reporter vector pGL4.32 (Promega K. K., E8491) having an NF-κB transcription responsive sequence incorporated thereinto had been stably introduced (hereinafter referred to as NF-κB/HEK293 cells) were generated and used for evaluation.
The NF-κB/HEK293 cells were suspended in a 10% fetal bovine serum-containing DMEM (Sigma, D6429) at 1.25×10 5 cells/mL and seeded at 80 μL/well in a clear bottom white 96-well plate (Corning Incorporated, 3610). The resultant was cultured for 2 hours in a CO2 incubator set at 37° C. and 5% CO2. Dilution series of the humanized 75E9STF8-1 in the medium were prepared and then added at 10 μL/well. The final concentration in each well was set in 11 steps (at an about 3-fold common ratio) from the maximum concentration of 100 nmol/L for the antagonistic activity evaluation, and 11 steps (at an about 3-fold common ratio) from the maximum concentration of 300 nmol/L for the agonistic activity evaluation. In addition, the same dilution series of STF8-1 were added as a control. In the antagonistic activity evaluation, 10 μL of TWEAK (PEPROTECH, 310-06) prepared in the medium was added to each well to a final concentration of 100 ng/mL. For the agonistic activity evaluation, 10 μL of the medium was added to each well. After culturing overnight at 37° C. with 5% CO2, a luciferase expression level was measured using a luciferase measurement reagent ONE-Glo™ Luciferase Assay System (Promega K.K., E6120) to quantify the NF-κB activation. The results are expressed in terms of an inhibition rate in a case where a value measured under the condition of 100 ng/mL of TWEAK stimulation is set to 0% inhibition and a value measured in the absence of TWEAK is set to 100% inhibition for in the antagonistic activity evaluation, and expressed in terms of an activation rate in a case where a value measured under the condition of 100 ng/mL of TWEAK stimulation is set to 100% and a value measured in the absence of TWEAK is set to 0% for in the agonistic activity evaluation. Measurements in the absence of TWEAK were performed by adding a medium instead of TWEAK. Furthermore, the data represent an average value of 2 trials (each trial was carried out in duplicate).
As a result, the humanized 75E9STF8-1 completely inhibited Fn14-mediated NF-κB activation by 100 ng/mL of TWEAK. In addition, the humanized 75E9STF8-1 did not induce NF-κB activation in the absence of TWEAK (FIG. 2). Thus, it was confirmed that the humanized 75E9STF8-1 has the antagonistic activity, but not the agonistic activity.
For the mouse in vivo pharmacological efficacy evaluation, 75E9 (mFc), STF8-1 (mFc), and 75E9STF8-1 (mFc) were prepared, respectively, based on the amino acid sequences of humanized tandem VHH 75E9, STF8-1, and humanized 75E9STF8-1. 75E9 (mFc) is an antibody in which Hinge, CH2, and CH3 of a mouse IgG1 heavy chain constant region are linked to the C terminal of 75E9 of the tandem VHH in Example 2 (SEQ ID NO: 15). STF8-1 (mFc) is an antibody in which the constant region of STF8-1 of Example 3 is substituted with mouse constant regions for both heavy and light chains (the heavy chain of STF8-1 (mFc) is set forth in SEQ ID NO: 16 and the light chain of STF8-1 (mFc) is set forth in SEQ ID NO: 17). 75E9STF8-1 (mFc) is an antibody consisting of a polypeptide (SEQ ID NO: 18) in which the N terminal of the STF8-1 (mFc) heavy chain is linked to the C terminal of 75E9 in Example 2 with a peptide linker (Gly⋅Gly⋅Gly⋅Gly⋅Ser (SEQ ID NO: 7))2 and a light chain of STF8-1 (mFc).
The amino acid sequences of CDR1, CDR2, and CDR3 of the first VHH of 75E9STF8-1 (mFc) and CDR1, CDR2, and CDR3 of the second VHH of 75E9STF8-1 (mFc) are the same as those of CDR1, CDR2, and CDR3 of the first VHH of humanized 75E9STF8-1 and CDR1, CDR2, and CDR3 of the second VHH of humanized 75E9STF8-1, respectively. Furthermore, the heavy chain variable region and the light chain variable region of STF8-1 (mFc) included in 75E9STF8-1 (mFc) are the same as those of the heavy chain variable region and the light chain variable region of STF8-1 included in humanized 75E9STF8-1, respectively.
It was confirmed that 75E9 (mFc) and 75E9STF8-1 (mFc) were subjected to the functional evaluation described in Example 6 and confirmed to have an Smad phosphorylation inhibitory activity. In addition, the functional evaluation described in Example 7 was performed, and it was confirmed that STF8-1 (mFc) and 75E9STF8-1 (mFc) had an antagonistic activity and 75E9STF8-1 (mFc) had no agonistic activity.
In mice, the in vivo pharmacological efficacy on muscle atrophy and muscle function were evaluated using a muscle weight and a grip strength as indices. A steroid-induced myopathy model (SIM model) by continuous administration of steroid was used as a muscle atrophy model animal, and the limb grip strength and the weight of an isolated quadriceps femoris muscle were measured after 14 days from repeated administration of the test substance.
The body weight and the grip strength of mice were measured, and 10 mice were assigned to each group so that the body weights and the grip strengths were equal among the groups. The groups are configured with a total of six groups of one normal group and five SIM model groups, in which the five SIM model groups are a vehicle-administered group, a 75E9 (mFc) group, an STF8-1 (mFc) group, a 75E9 (mFc)+STF8-1 (mFc) group, and a 75E9STF8-1 (mFc) group. Corticosterone (dissolved in filtered water mixed with 1% ethanol at a concentration of 100 μg/mL) was administered continuously to the SIM model group by free drinking for 14 days to induce muscle atrophy. The normal group was allowed to freely drink filtered water. Administrations of a test substance 1 and test substance 2 were started on the same day as the administration of corticosterone. The details of administration of the test substance for each group are shown in Table 1. The dose of the 75E9STF8-1 (mFc) group was set so that the molar concentration was approximately the same as the dose of each group administered alone. On the 14th day after the start of administration of the test substance, the grip strength was measured using a small animal grip strength measuring device (MELQUEST Ltd., GPM-100). Thereafter, the mouse was exsanguinated to death under anesthesia, and the quadriceps femoris muscle was removed and weighed.
As a result, 75E9 (mFc) or STF8-1 (mFc) partially suppressed the skeletal muscle atrophy and decrease of the grip strength in the SIM model. Furthermore, a mixed treatment of 75E9 (mFc) and STF8-1 (mFc) exhibited significantly stronger inhibitory actions on the skeletal muscle atrophy and the grip strength reduction than the administration of each alone. In addition, 75E9STF8-1 (mFc) exhibited significantly stronger inhibitory actions on the skeletal muscle atrophy and the grip strength reduction than the mixed treatment of 75E9 (mFc) and STF8-1 (mFc) (
In vivo pharmacological efficacy on a lean thigh weight was evaluated in a cynomolgus monkey in a steroid-induced myopathy model after 4 weeks from administration of the test substance. It is noted that the lean weight is a total weight of muscle, bone, and blood, excluding fat, and is known to correlate with the skeletal muscle weight (Walowski C O et al., Nutrients. 2020, Vol. 12, 755).
The lean thigh weight of the cynomolgus monkey was measured using a bone densitometer (Discovery C, Hologic, Inc.) using dual energy X-ray absorptiometry, and the monkeys were equally divided into four groups. The groups are configured with a total of four groups of a normal group (n=2) and three SIM model groups (n=3 for each group), and the three groups of the SIM models are a vehicle-administered group, a humanized 75E9STF8-1 group, and a Bimagrumab group. Prednisolone (30 mg/3 mL/kg) was subcutaneously administered to the back of the SIM model group twice a day for 4 to 5 days/week to induce muscle atrophy. Physiological saline was similarly subcutaneously administered to the back of the normal group. The test substance was PBS for the normal group and the vehicle-administered group, 40 mg/2.4 mL/kg of humanized 75E9STF8-1 for the humanized 75E9STF8-1 group, and 30 mg/2.4 mL/kg of Bimagrumab for the Bimagrumab group, each of which was intravenously administered on day 1 of the administration of prednisolone. The dosage was set so that the humanized 75E9STF8-1 and Bimagrumab were administered at the same number of moles. Measurement of the lean thigh weight was carried out after 4 weeks from the administration of the test substance. The lean weight of each of the left and right thighs was measured, and an average value thereof was used as the measured value of the individual.
As a result, in the SIM model monkeys, the lean thigh weight of the humanized 75E9STF8-1 group was significantly heavier than that of the vehicle-administered group. No significant difference was observed between the Bimagrumab group and the vehicle-administered group (
The multispecific antibody of the present invention is useful for prevention or treatment of various diseases in which human ActRIIA, human ActRIIB, and human Fn14 are involved in pathogenesis. In addition, the polynucleotides, the expression vectors, the transfected host cells, and the method for producing the antibody of the present invention are expected to be useful for production of the multispecific antibody.
In the number heading <223> of the following sequence listing, description of “Artificial Sequence” is made. Specifically, the nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing is a nucleotide sequence encoding a polypeptide including the first VHH of the multispecific antibody, the second VHH of the multispecific antibody, and the heavy chain of an antibody binding to Fn14 of the multispecific antibody, and the nucleotide sequence represented by SEQ ID NO: 3 is a nucleotide sequence encoding the light chain of the antibody binding to Fn14 of the multispecific antibody. The amino acid sequence represented by SEQ ID NO: 2 is a polypeptide including the first VHH of the multispecific antibody encoded by SEQ ID NO: 1, the second VHH of the multispecific antibody, and the heavy chain of the antibody binding to Fn14 of the multispecific antibody, and the amino acid sequence represented by SEQ ID NO: 4 is the amino acid sequence of the light chain of the antibody binding to Fn14 of the multispecific antibody encoded by SEQ ID NO: 3. SEQ ID NOS: 5 to 12 are the amino acid sequences of exemplary peptide linkers. The nucleotide sequence represented by SEQ ID NO: 13 is a nucleotide sequence encoding the heavy chain of the antibody binding to Fn14, and the amino acid sequence represented by SEQ ID NO: 14 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 13. The amino acid sequence represented by SEQ ID NO: 15 is the amino acid sequence of an antibody in which a mouse constant region is linked to the C terminal of the tandem VHH. The amino acid sequence represented by SEQ ID NO: 16 is the amino acid sequence of the heavy chain of the antibody binding to Fn14, and the amino acid sequence represented by SEQ ID NO: 17 is the amino acid sequence of the light chain of the antibody binding to Fn14. The amino acid sequence represented by SEQ ID NO: 18 is a polypeptide including the tandem VHH and the heavy chain of the antibody binding to Fn14.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2021-003805 | Jan 2021 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2022/000661 | 1/12/2022 | WO |
